目的 探討正天膠囊聯(lián)合鹽酸洛美利嗪膠囊治療偏頭痛的臨床療效。方法 選擇2020年4月—2021年4月在駐馬店市中心醫(yī)院治療的102例偏頭痛患者，根據(jù)藥物使用的差別分為對照組和治療組，每組各51例。對照組口服鹽酸洛美利嗪膠囊，5 mg/次，2次/d；治療組在對照組基礎(chǔ)上口服正天膠囊，0.9 g/次，3次/d。兩組均用藥2周。觀察兩組患者臨床療效，比較治療前后兩組患者腦血流速度、臨床癥狀，PSQI、MSQ和VAS評分，及血清血管性血友病因子（vWF）、垂體腺苷酸環(huán)化酶激活肽（PACAP）、5-羥色胺（5-HT）、β-內(nèi)啡肽（β-EP）和降鈣素基因相關(guān)肽（CGRP）水平。結(jié)果 經(jīng)治療，對照組和治療組的總有效率分別為84.31%和98.04%（P<0.05）。經(jīng)治療，兩組大腦后動脈（PCA）、大腦前動脈（ACA）、基底動脈（BA）、大腦中動脈（MCA）、椎動脈（VA）的血流速度均降低（P<0.05），且治療組更顯著（P<0.05）。經(jīng)治療，兩組頭痛發(fā)作次數(shù)和頭痛持續(xù)時間上均改善（P<0.05），且治療組更明顯（P<0.05）。經(jīng)治療，兩組患者PSQI評分和MSQ評分明顯升高，而VAS評分明顯降低（P<0.05），且治療組評分明顯好于對照組（P<0.05）。經(jīng)治療，兩組患者血清CGRP、vWF、β-EP、PACAP水平明顯降低，而5-HT水平明顯升高（P<0.05），且治療組血清學(xué)指標(biāo)水平明顯好于對照組（P<0.05）。結(jié)論 正天膠囊聯(lián)合鹽酸洛美利嗪膠囊治療偏頭痛能夠有效改善患者臨床癥狀，促進(jìn)腦血流情況改善，改善機(jī)體細(xì)胞因子水平，提高患者睡眠及生活質(zhì)量。

Objective To investigate the clinical effect of Zhengtian Capsules combined with lomerizine in treatment of migraine. Methods Patients (102 cases) with migraine in Zhumadian Central Hospital from April 2020 to April 2021 were divided into control and treatment groups according to different treatments, and each group had 51 cases. Patients in the control group were po administered with Lomerizine Hydrochloride Capsules, 5 mg/time, twice daily. Patients in the treatment group were po administered with Zhengtian Capsules, 0.9 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical evaluation was evaluated, the cerebral blood flow velocity, the clinical symptoms, the scores of PSQI, MSQ, and VAS, and the levels of serum CGRP, vWF, β-EP, PACAP, and 5-HT in two groups before and after treatment were compared. Results After treatment, the effective rates of the control group and the treatment group were 84.31% and 98.04%, respectively (P<0.05). After treatment, the blood flow velocities of PCA, ACA, BA, MCA, and VA were significantly decreased in two groups (P<0.05), and which the treatment group decreased more significantly (P<0.05). After treatment, the frequency of headache attacks and the duration of headache were improved in two groups (P<0.05), and which in the treatment group was the most improved (P<0.05). After treatment, the PSQI score and MSQ score in two groups were significantly increased, while the VAS score was significantly decreased (P<0.05), and these scores in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the levels of serum CGRP, vWF, β-EP, and PACAP in two groups significantly decreased, while the level of 5-HT was significantly increased (P<0.05), and these serum indexes level in the treatment group was significantly better than that in the control group (P<0.05). Conclusion Zhengtian Capsules combined with lomerizine in treatment of migraine can effectively improve the clinical symptoms, promote the improvement of cerebral blood flow, improve the level of cytokines, and improve the sleep and quality of life.

R971

河南省科技研發(fā)專項項目（172102310685）